Global Antibody Production Market to Surpass USD 41.2 Billion by 2031 Amid Growing Biologics Demand and Technological Breakthroughs
[Boston, 4 June 2025] – Clearview Market Insights (CVMI) projects that the global antibody production market will grow from USD 18.1 billion in 2024 to USD 41.2 billion by 2031, achieving a robust compound annual growth rate (CAGR) of 12.6 percent. This expansion is driven by the increasing demand for monoclonal antibodies (mAbs), rapid biologics development pipelines, and ongoing innovation in cell-line engineering as well as continuous manufacturing.
“Antibodies have become foundational to modern medicine—from targeted cancer therapy to next-generation diagnostics,” said Dr. Ravi Chandra, lead biomanufacturing analyst at CVMI. “What was once a lab-scale tool has now matured into a multibillion-dollar industrial backbone supporting personalized healthcare, pandemic response, and global biosimilar growth.”
Request Sample @ https://clearviewmarketinsights.com/report-details/global-antibody-production-market/
Key Numbers
- 2024 Market Value: USD 18.1 billion
- 2031 Market Value: USD 41.2 billion
- Seven-Year CAGR: 12.6 percent
- Therapeutic Applications Share (2024): 53%
- North America Market Share: 38%
Market Drivers
- Rising Biologic Therapies
- Contract Manufacturing Demand
- Technological Advancements
- Global Health Preparedness
- Government Incentives
Company Highlights
- Lonza launched Ibex® Design, reducing the timelines for clinical-scale antibody production by 40 percent.
- Samsung Biologics has opened its fourth plant in Incheon, thereby doubling its antibody production capacity.
- WuXi Biologics commenced development of a mega-facility in Singapore with modular POD-based architecture.
- Thermo Fisher Scientific strengthened its biologics CDMO business through the acquisition of Belgium-based Henogen.
Regional Insights
- North America: Dominates the market with advanced CDMO infrastructure and high biologic drug consumption.
- Asia-Pacific: Fastest-growing region; China and India are scaling domestic production through government grants and tech transfers.
- Europe: Hosts a strong biosimilar manufacturing base.
- Latin America & MEA: Emerging interest in local antibody fill-finish and diagnostic assay development.
Technology Trends
- AI-driven Bioprocessing
- Modular Biomanufacturing
- Cell-Line Optimization
- Single-Use Systems
Milestones (2024–2025)
Quarter |
Event |
Impact |
Q1 2024 |
Lonza launches Ibex® Design |
40% faster process development cycle |
Q2 2024 |
Samsung Biologics opens new facility |
Global antibody production capacity up 25% |
Q3 2024 |
Thermo Fisher expands CDMO services |
Strengthens diagnostics-focused antibody supply |
Q1 2025 |
WuXi Biologics breaks ground in Singapore |
Modular bioproduction model enters APAC market |
For more insights, visit https://clearviewmarketinsights.com/report-store
About Clearview Market Insights
Clearview Market Insights is a global research and consulting firm that delivers forward-looking intelligence across more than 100 healthcare, biotechnology, and pharmaceutical markets. Our analysts synthesize real-time data, executive insights, and strategic models to support decision-making at the highest levels.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369